Is compounded semaglutide or tirzepatide the same as Wegovy or Zepbound?
No: compounded semaglutide and tirzepatide are made by state-licensed pharmacies with the drug in Wegovy or Zepbound, but they are not the same product, they are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness or quality before they are sold. The trial results printed on the brand labels (STEP, SURMOUNT) were measured with the brand products. Ask which pharmacy fills the prescription, whether it is a 503A pharmacy or a 503B outsourcing facility, and whether the formula adds ingredients such as B12 or niacinamide. Check the FDA's warning-letter list before you buy.
Answer dated October 16, 2026; reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).Made with the drug in Wegovy or Zepbound, but not the same product, and not FDA-approved.
What they share
- Made with the drug in the brand product (semaglutide or tirzepatide)
- Mechanism of action; programs often follow the brand dosing ladder
- Expected side effects, although compounded products have no trial results of their own
Different
- FDA approval. Branded is approved finished drug. Compounded is prepared under 503A/503B federal exceptions — not FDA-approved as finished products.
- Manufacturing. Branded: cGMP. 503B: cGMP. 503A: USP standards, not cGMP.
- Concentration / excipients / device. Vary.
- Pricing. Brand list prices run about $1,086 (Zepbound) to $1,349 (Wegovy) a month; manufacturer self-pay starts at $299 (Zepbound vials) and $349 (Wegovy pens). Compounded medians in our October 15, 2026 index: $144 (tirzepatide) and $94 (semaglutide; NexLife’s price as of November 6, 2026) a month.
- Regulatory stability. Compounded supply subject to FDA shortage rules and state board oversight.
Prefer branded when
- Insurance covers it
- Need indication-specific approved label (Wegovy CV, Zepbound OSA)
- Prefer calibrated pen injector
Compounded reasonable when
- Cash-pay (no coverage, high deductible, excluded)
- Comfortable with 503A/503B framework
- Accept that finished product isn't FDA-approved
Evaluating a compounded provider
- Are pharmacy partners named?
- Is 503A or 503B classification disclosed?
- What standards (USP <797>, <85>) are referenced?
- Will the pharmacy share batch test results?
- Clinical oversight clearly described?
Example: NexLife's plan pages, read October 15, 2026, name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).